Connect with us

International Circuit

PerkinElmer announces financial results for the second quarter of 2020

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 5, 2020.

The Company reported GAAP earnings per share from continuing operations of $1.23, as compared to GAAP earnings per share from continuing operations of $0.62 in the second quarter of 2019. GAAP revenue for the quarter was $811.7 million, as compared to $722.5 million in the second quarter of 2019. GAAP operating income from continuing operations for the quarter was $175.6 million, as compared to $91.7 million for the same period a year ago. GAAP operating profit margin was 21.6% as a percentage of revenue, as compared to 12.7% in the second quarter of 2019.

Adjusted earnings per share from continuing operations for the quarter was $1.57, as compared to $1.00 in the second quarter of 2019. Adjusted revenue for the quarter was $811.9 million, as compared to $722.7 million in the second quarter of 2019. Adjusted operating income from continuing operations for the quarter was $228.2 million, as compared to $146.0 million for the same period a year ago. Adjusted operating profit margin was 28.1% as a percentage of adjusted revenue, as compared to 20.2% in the second quarter of 2019.

Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.

“I could not be more proud of how we at PerkinElmer have met the obstacles that have faced us the past few months. We have proven to be a resilient, responsive, and agile organization,” said Prahlad Singh, president and chief executive officer of PerkinElmer. “Our strong second quarter results were truly a team effort and further reinforce the diversity of our business from a portfolio and geographic standpoint.”

Financial Overview by Reporting Segment for the Second Quarter

Discovery & Analytical Solutions

  • Second quarter 2020 revenue was $391.0 million, as compared to $434.0 million for the second quarter of 2019. Reported revenue decreased 10% and organic revenue decreased 10% as compared to the second quarter of 2019.
  • Second quarter 2020 operating income from continuing operations was $39.4 million, as compared to $57.7 million for the comparable prior period.
  • Second quarter 2020 adjusted operating income was $57.4 million, as compared to $81.5 million for the second quarter of 2019.

Diagnostics

  • Second quarter 2020 revenue was $420.7 million, as compared to $288.6 million for the second quarter of 2019. Reported revenue increased 46% and organic revenue increased 48% as compared to the second quarter of 2019.
  • Second quarter 2020 operating income from continuing operations was $160.3 million, as compared to $49.3 million for the comparable prior period.
  • Second quarter 2020 adjusted operating income was $189.6 million, as compared to $79.7 million for the second quarter of 2019.

Third Quarter 2020 Guidance

For the third quarter of 2020, the Company forecasts GAAP revenue in the range of $760 million to $860 million, GAAP earnings per share from continuing operations of $0.85 to $1.20 and, on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share of $1.18 to $1.53.

Conference Call Information

The Company will discuss its second quarter 2020 results and its outlook for business trends in a conference call on July 28, 2020 at 5:00 p.m. Eastern Time. To access the call, please dial (720) 405-2250 prior to the scheduled conference call time and provide the access code 4468217.

A live audio webcast of the call will be available on the Investors section of the Company’s Web site, www.perkinelmer.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Company’s Web site for a two-week period beginning approximately two hours after the call.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our failure to adequately protect our intellectual property; (7) the loss of any of our licenses or licensed rights; (8) our ability to compete effectively; (9) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (10) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (11) disruptions in the supply of raw materials and supplies; (12) the manufacture and sale of products exposing us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with healthcare industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) significant disruption in our information technology systems, or cybercrime; (19) our ability to obtain future financing; (20) restrictions in our credit agreements; (21) discontinuation or replacement of LIBOR; (22) the United Kingdom’s withdrawal from the European Union; (23) our ability to realize the full value of our intangible assets; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. –Businesswire

Copyright © 2024 Medical Buyer

error: Content is protected !!